Skip to navigation Skip to content

Treating RRMS


Modifying the Disease Course

The Food and Drug Administration (FDA) has approved more than a dozen medications for the treatment of relapsing forms of MS, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses). Research has shown that all the MS medications can:

  • reduce the number of relapses (also called attacks or exacerbations)
  • limit new MS activity (new areas of damage called plaques or scars) in the central nervous system (CNS) and seen on magnetic resonance imaging (MRI)
  • slow disease worsening (progression)

Years of research suggest that starting one of these medications soon after the diagnosis of MS is the most effective way to manage the MS disease process. These MS medications modify the MS disease course and are also known as disease-modifying treatments (DMT).

Each of the disease-modifying treatments have side effects and risks associated with them.  Starting a DMT or switching to a different DMT are decisions best made by the person with MS and his or her MS healthcare provider, after a conversation about how the medication is taken, the side effects, risks and cost.

Read more in The MS Disease-Modifying Medications (.pdf).


Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.


Rehabilitation specialists have an important role from the time of diagnosis helping people function optimally in spite of their MS, including enhancing mobility and promoting safety and independence.


The National MS Society is Here to Help

Newly Diagnosed
If you or somone close to you has recently been diagnosed, access our MS information and resources.

Start Here

Start Here
© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.